

**SUPPLEMENTARY INFORMATION:** The single-source award will support the National AIDS Control Program of Sierra Leone (SL) in the Ministry of Health and Sanitation to implement HIV strategic information and laboratory strengthening activities in SL. This award will build and strengthen laboratories that are equipped with the appropriate diagnostic technologies, trained and skilled staff, and systems that have the capability to provide efficient services. It will also strengthen SI systems, data quality assurance and capacity of staff responsible for managing facility-based survey and surveillance data operating at national and subnational levels. As the mandated institution to provide HIV treatment clinical services and guidelines in SL, the Sierra Leone Ministry of Health and Sanitation is in a unique position to conduct this work. The National HIV/AIDS control program is one of the specialized programs within the Ministry of Health.

#### Summary of the Award

*Recipient:* Sierra Leone Ministry of Health and Sanitation.

*Purpose of the Award:* The purpose of this award is to build laboratory and SI capacity to improve the provision of HIV testing, treatment, and retention in line with HIV epidemic control and 95–95–95 targets. The award will build and strengthen laboratories that are equipped with the appropriate diagnostic technologies, trained and skilled staff, and systems that have the capability to provide efficient services.

*Amount of Award:* The approximate year 1 funding amount will be \$450,000 in Federal Fiscal Year (FFY) 2022 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

*Period of Performance:* September 30, 2022 through September 29, 2027.

Dated: February 1, 2022.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–02407 Filed 2–3–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA–CE–22–013: Rigorous Evaluation of Community-Centered Approaches for the Prevention of Community Violence.

*Date:* June 28–29, 2022.

*Time:* 8:30 a.m.–5:30 p.m., EDT.

*Place:* Videoconference.

*Agenda:* To review and evaluate grant applications.

#### FOR FURTHER INFORMATION CONTACT:

Mikel Walters, Ph.D., Scientific Review Official, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, [MWalters@cdc.gov](mailto:MWalters@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–02380 Filed 2–3–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Delegation of Authority

Notice is hereby given that the Director, Centers for Disease Control and Prevention (CDC), has delegated to the Chief Operating Officer, CDC, without the authority to redelegate, the authority vested in the Secretary of HHS by section 212(1) of the Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (FY 19 HHS Appropriations Act) Public Law 115–245, division B, title II, or substantially similar authorities vested in the Secretary in the future by Congress, in order to carry out international health activities.

Section 212(1) of the FY19 HHS Appropriations Act permits the Secretary of HHS to exercise authority equivalent to that available to the Secretary of State under 22 U.S.C 2669(c) to award personal services contracts for work performed in foreign countries. The authority delegated herein includes the authority to determine the necessity of negotiating, executing, and performing such contracts without regard to statutory provisions as related to the negotiation, making, and performance of contracts and performance of work in the United States.

The authority under section 212(1) is immediately revoked in the event that any subsequent fiscal year HHS appropriations act does not contain the provision currently in section 212(1) or substantially similar authority.

The Chief Operating Officer, CDC, shall consult with the Secretary of State and relevant Chief of Mission to ensure that this authority is exercised in a manner consistent with section 207 of the Foreign Service Act of 1980 and other applicable statutes administered by the Department of State.

This delegation supersedes the delegation of similar name, approved by the Director, CDC, on March 17, 2020.

This delegation became effective on January 31, 2022. The Director, CDC, affirms and ratifies any actions taken that involve the exercise of the authority delegated herein prior to the effective date of this delegation.

**Sherri A. Berger,**

*Chief of Staff, Centers for Disease Control and Prevention.*

[FR Doc. 2022–02328 Filed 2–3–22; 8:45 am]

**BILLING CODE 4163–18–P**